MedPath

Remsima

Brand Name: Remsima

Generic Name: Infliximab

Active
Registration Number

BR-907

Dosage Form

Lyophilized Powder for Concentrate for Solution for Infusion (IV)

Issuance Date

August 2, 2023

Expiry Date

May 14, 2028

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage Strength100mg
Packaging20 mL Type I glass vial (Box of 1's)

Classification

C
Classification
Prescription Drug (RX)
A
Application
Renewal (Correction)
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

InfliximabActive
Monograph: Infliximab

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform